Navigation Links
Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Date:2/8/2008

tients were titrated every three to four days to an optimal dose (maximum dose of 375 mg/day). Patients were then maintained at the optimal dose for the remainder of the study. The study was conducted at 40 centers across the U.S. and Canada.

The primary efficacy endpoint of the study was to compare the change in the Hamilton Rating Scale for Depression (HAMD-17) total score from baseline to the end of the study in the once-daily trazodone group versus the placebo group. Statistical significance was achieved for the primary endpoint (p value of 0.0183) and under additional methods of analysis as specified in the Statistical Analysis Plan (SAP). The overall drop out rate in the study was 25.5%. The drop out rate was 21% in the placebo group and 30.2% in the once-daily trazodone group. In the once-daily trazodone group, 4% of patients discontinued treatment due to somnolence or sedation. The drop out rate observed in this study is comparable to drop out rates in typical depression studies.

Based on discussions with the FDA, Labopharm expects to submit an NDA for its once-daily formulation of trazodone under Section 505(b)(2) of the U.S. Federal Food, Drug and Cosmetic Act, which typically applies to reformulations of drugs that are already approved and being marketed, allowing the Company to leverage existing efficacy and safety data on trazodone. The Agency advised the Company that one positive Phase III study is required for the formulation to be approved.

About Trazodone

Trazodone is an atypical anti-depressant that acts as a dual serotonin agonist and serotonin reuptake inhibitor (SARI). Trazodone appears to increase serotonin activity via three mechanisms: the activation of neuronal serotonin receptors; the inhibition at the neuronal serotonin feedback system which regulates the action of serotonin; and the inhibition of the re-uptake of serotonin. Trazodone also helps to treat depression by improving sleep as a result of sedative effe
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
2. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
3. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
4. Labopharm Reports Results for Third Quarter Fiscal 2007
5. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
6. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
7. Labopharm appeals FDAs decision on once-daily tramadol
8. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
9. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
10. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
11. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Wright & Schulte LLC has filed a DePuy Pinnacle ... Johnson & Johnson, on behalf of an Ohio man who ... DePuy Pinnacle hip replacement and had to undergo revision surgery ... DePuy hip lawsuit was filed July 7, 2014, in the ... where DePuy Pinnacle Hip lawsuit litigation is underway . ...
(Date:7/12/2014)... New York, NY (PRWEB) July 12, 2014 ... (the National Institute of Standards and Technology), the June ... up the electronic discovery world. It was ... was finally in, depending on whether it was seen from ... But this much is fact, there is now precedent ...
(Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
(Date:7/12/2014)... Restore My Vision Today is a ... a couple boasting very impressive credentials on the field ... Today as a way to help consumers do without ... their respective patients’ treatments . , In ... trove of pertinent information relevant to eye care like:, ...
(Date:7/12/2014)... The largest pure occupational medicine company in the ... it will be opening its fifth Georgia center in ... Atlanta-based Nova Medical Centers’ locations. The Augusta facility ... and will be open from 8:30 a.m. to 6 ... philosophy of rapid return-to-work and decreased treatment times for ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
... Students to Get Fit By Finals, , Awards School with ... Chicago Bulls legend BJ Armstrong is rallying Chicago ... new national campaign called Get Fit By Finals . ... "got milk?" Body By Milk(R) Campaign and NBA FIT, the NBA,s ...
... galectin-3 may serve as treatment target against disease ... -- A newly identified marker for prostate cancer ... treatment, University of Michigan researchers say. , Previous ... marker galectin-3 are linked with neoplastic progression in ...
... Will Earn Decision Resources, Clinical Gold Standard Status ... a New Report from Decision ResourcesWALTHAM, Mass., March ... leading research and advisory firms for pharmaceutical and ... a therapy,s effect on the rate of mortality ...
... 2008 Frost & Sullivan European Human Growth ... to Ferring Pharmaceuticals. The award is in ... injection for human growth hormone (hGH). The ... VISION X, innovative no-needle delivery systems for ...
... WELLINGTON, Fla., March 25 The Quantum Group, Inc. ... announced it has implemented a reallocation of ... the PWeR(TM) (pronounced POWER) platform. As Quantum continues ... the Company expects for the PWeR platform, it has ...
... Osteoarthritis Sufferers to Live Fit by Thinking Fit, Eating ... 25 Today, Bob Greene, best-selling author and personal ... the 27 million Americans who suffer from osteoarthritis (OA) ... Pharmaceuticals (Nasdaq: ENDP ), the MOVE (Managing ...
Cached Medicine News:Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 3Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 4Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 5Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 2Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 3Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 3Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 2Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 3Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 4Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 5Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 2Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 3Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 4Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 5Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 6Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 7
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... , SOUTH SAN FRANCISCO, Calif., July 8 Rigel Pharmaceuticals, ... Company plans to host a conference call on Thursday, July ... Members of Rigel,s senior management team and the principal investigator ... 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the ...
... OAKS, Calif., July 7 Amgen (Nasdaq: ... head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in ... advanced breast cancer met its primary and secondary endpoints ... was demonstrated for both delaying the time to the ...
Cached Medicine Technology:Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8